AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
Business Wire•08/10/2026•06:02 ET
8
Key Highlights
- ➤Q1 net sales $80.9 million, up 6.9% year over year
- ➤Med Tech sales $39.9 million, up 13.2% year over year
- ➤Adjusted EBITDA $5.0 million, versus $2.2 million a year earlier
- ➤Fiscal 2027 guidance reiterated: net sales $336.0M-$341.0M
- ➤Eric Honroth named CEO effective November 2, succeeding retiring Jim Clemmer
Expert Statements
Jim Clemmer, President and Chief Executive Officer of AngioDynamics
“Our first quarter results reflect the continued, consistent execution we've built into this business,”
Jim Clemmer, President and Chief Executive Officer of AngioDynamics
“Med Tech again led our growth, highlighted by Auryon's 21(st) consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform.”
Jim Clemmer, President and Chief Executive Officer of AngioDynamics
“We remain focused on the fundamentals that have driven our performance over the past several years, and we're confident in our ability to deliver on the outlook we've laid out for fiscal 2027.”
Jim Clemmer, President and Chief Executive Officer of AngioDynamics
“As I shared previously, after ten years leading this company, I have decided to retire, and the Board has completed a comprehensive search for my successor.”
Jim Clemmer, President and Chief Executive Officer of AngioDynamics
“I'm pleased to share that Eric Honroth will become our next President and Chief Executive Officer.”
Jim Clemmer, President and Chief Executive Officer of AngioDynamics
“He brings the right experience and leadership to build on the foundation we've established, and I will remain closely involved to ensure a smooth transition.”
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA
Get started
Create a free account to read the full story.